Drug Profile
Research programme: PARP inhibitors - Rocket/Genentech
Latest Information Update: 09 Jan 2018
Price :
$50
*
At a glance
- Originator Genentech; Inotek Pharmaceuticals
- Developer Genentech
- Class Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
- 21 Apr 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 02 Aug 2006 Preclinical trials in Cancer in USA (unspecified route)